Related references
Note: Only part of the references are listed.Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity
Xing Du et al.
CANCER RESEARCH (2008)
Acquired resistance to rituximeb is associated with chemotherapy resistance resulting from decreased Bax and Bak expression
Scott H. Olejniczak et al.
CLINICAL CANCER RESEARCH (2008)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma
Andrew G. Polson et al.
BLOOD (2007)
Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells
Amadeo M. Parissenti et al.
ANTI-CANCER DRUGS (2007)
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy
Ali R. Jazirehi et al.
CANCER RESEARCH (2007)
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
MSK Sutherland et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab
RM Seliem et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2006)
Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Risto S. Cvetkovic et al.
BIODRUGS (2006)
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
SO Doronina et al.
BIOCONJUGATE CHEMISTRY (2006)
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease
N Yazawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Immunotherapy for non-Hodgkin's lymphoma: Monoclonal antibodies and vaccines
DG Maloney
JOURNAL OF CLINICAL ONCOLOGY (2005)
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides
MMC Sun et al.
BIOCONJUGATE CHEMISTRY (2005)
Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-hodgkin's lymphoma B cells by rituximab
AR Jazirehi et al.
CANCER RESEARCH (2004)
Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains
C Bezombes et al.
BLOOD (2004)
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates
CL Law et al.
CLINICAL CANCER RESEARCH (2004)
Identification and validation of cell surface antigens for antibody targeting in oncology
P Carter et al.
ENDOCRINE-RELATED CANCER (2004)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Immunophenotypic analysis of Waldenstrom's macroglobulinemia
JF San Miguel et al.
SEMINARS IN ONCOLOGY (2003)
Protease-mediated fragmentation of p-amidobenzyl ethers:: A new strategy for the activation of anticancer prodrugs
BE Toki et al.
JOURNAL OF ORGANIC CHEMISTRY (2002)
Lymphoplasmacytic lymphoma with monoclonal gammopathy-related pseudo-Gaucher cell infiltration in bone marrow and spleen - Diagnostic and therapeutic dilemmas
T Robak et al.
LEUKEMIA & LYMPHOMA (2002)
Recurrent B-cell neoplasms after rituximab therapy: An immunophenotypic and genotypic study
PG Chu et al.
LEUKEMIA & LYMPHOMA (2002)
Share Paper
